Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

Exclusion Criteria

• •Has taken or plans to take any lipid-lowering medications or medications known to alter lipoprotein metabolism within 4 weeks of Screening, (e.g. statins, fibrates, niacin, cholesterol absorption inhibitors, bile acid-sequestrants, fish oils, PCSK9 inhibitors, red yeast rice, glucocorticoids, and anabolic agents).
• •Current, or any previous history of New York Heart Association (NYHA) class III or IV heart failure or left ventricular ejection fraction \< 30%.
• •Uncontrolled hypertension defined as either systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg prior to the Baseline visit, taken as the average of triplicate measurements. One triplicate retest will be allowed during the same visit, at which point if the retest result is no longer exclusionary, the participant may be randomized.
• •HDL-C \> 60 mg/dL if male or \>70 mg/dL if female, at Screening.
• •An eGFR \< 45 mL/min/1.73m2 at the Screening visit or history of end-stage renal disease (ESRD).
• •Active liver disease, defined as any known current infectious, neoplastic, or metabolic pathology of the liver; unexplained elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 x upper limit of normal (ULN); or total bilirubin \> 2 x ULN at the and/or Screening visit.
• •History of stroke, chronic seizures, or major neurological disorder.
• •Participant with a history of neoplastic disease. Note: Participant treated non-melanoma skin carcinoma, and other malignancies which have been successfully treated ≥ 5 years prior to the Screening visit where, in the judgment of both the PI and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the Screening visit.
• •Has participated in another investigational drug study within 30 days of Screening